Revision Year: 2025
INLURIYO tablets contain imlunestrant, an estrogen receptor antagonist. The chemical name for imlunestrant tosylate is (5R)-5-(4-(2-(3-(flouromethyl)azetidin-1-yl)ethoxy)phenyl)-8-(trifluoromethyl)-5H-(1)benzopyrano(4,3-c)quinolin-2-ol, tosylate salt (1:1). Imlunestrant tosylate is a white to practically white to yellow powder with the empirical formula C29H24F4N2O3.C7H8O3S and a molecular weight 696.71 g/mol. The aqueous solubility of imlunestrant tosylate is slightly soluble at low pH, insoluble at neutral pH, and sparingly soluble at high pH. The chemical structure of imlunestrant tosylate is shown below:
INLURIYO are tablets for oral administration. Each INLURIYO tablet is available as capsule-shaped, film-coated tablet that contains 200 mg imlunestrant (equivalent to 265.66 mg imlunestrant tosylate). The tablet contains the following inactive ingredients: croscarmellose sodium, hydroxypropyl cellulose, magnesium stearate, and microcrystalline cellulose. The tablets are coated using a common white coating, which consists of polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide.
| Dosage Forms and Strengths |
|---|
|
INLURIYO tablets contain 200 mg imlunestrant and are white, film coated-capsule-shaped tablets, with "LILLY" on one side and "1717" and elongated 4-point starburst on the other side. |
| How Supplied |
|---|
|
INLURIYO 200 mg tablets are white capsule-shaped tablets with "LILLY" on one side and "1717" and an elongated 4-point starburst on the other side. INLURIYO 200 mg tablets are supplied in either a 28-count or 56-count bottle configuration.
Marketed by: Lilly USA, LLC, Indianapolis, IN 46285, USA |
| Drug | Countries | |
|---|---|---|
| INLURIYO | Austria, Lithuania, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.